Peptide clinics: 12 questions to ask before you pay

Why ask at all

Peptide clinics range from physician practices that prescribe approved drugs and monitor patients closely to storefronts that sell injectable vials with little more than an online form. From the outside they can look the same. The questions below are the ones that tell them apart, and each answer can be checked against an official source. We name no clinics, because the point is to let you judge any of them.

Questions about who is treating you

1. Who will prescribe, and are they licensed where you live?

Ask for the prescriber's name and the state where they are licensed. Medical licences are issued by state boards, and the best place to start is your state medical board's licence lookup; DocInfo, a free search run by the Federation of State Medical Boards, covers disciplinary history across every state ¹². A clinic that will not tell you who signs your prescription is a clinic to leave.

2. Will a clinician evaluate you before prescribing?

A prescription should follow an assessment of your history, your other medicines and your goals, not a checkout page. Ask what that assessment involves, whether it includes blood tests, and who reviews the results.

Questions about what you are getting

3. Is it an approved drug, a compounded drug or a research chemical?

These are three different things. Approved drugs, such as semaglutide High sold as Wegovy, went through FDA review for a specific use. Compounded drugs are made by a pharmacy for a patient, and FDA says plainly that they are not FDA-approved ³. Products labelled research use only are not made or tested for people at all, whatever a seller implies.

4. Which pharmacy makes it, and is it a 503A pharmacy or a 503B outsourcing facility?

The answer tells you who checks the pharmacy. Under section 503A, a licensed pharmacist in a state-licensed pharmacy compounds for individual patients, and the state board of pharmacy has primary responsibility for day-to-day oversight ³. A 503B outsourcing facility registers with FDA, is inspected by FDA on a risk-based schedule and must follow current good manufacturing practice ³. FDA publishes the list of registered outsourcing facilities, last updated September 30, 2026, and a facility must re-register every year ⁴. Ask for the pharmacy's name and check it.

5. Can this substance legally be compounded?

Not every peptide can. A 503A pharmacy may compound from bulk ingredients only within the conditions the law sets, and FDA sorts nominated substances into interim categories ⁵. BPC-157 Low is the best-known example of a gap: FDA placed it in Category 2 on September 29, 2023, citing possible immune reactions and product-quality concerns ⁶, and although it was taken out of Category 2 in April 2026, as of October 2, 2026 it sits in none of the categories on FDA's list, last updated May 14, 2026, and is not on the 503A list ⁵. Our guide to FDA's categories explains the system.

6. How was it tested, and can you see the results?

Outsourcing facilities must meet manufacturing standards that include testing ³. For any product, ask for its certificate of analysis: what was tested (identity, strength, sterility, endotoxin), by whom and when, and for which batch. A clinic that cannot produce one cannot tell you what is in the vial.

Questions about whether it works and what could go wrong

7. What is the evidence for your goal?

Ask what studies support the treatment for what you want it to do, and whether they were in people. The Federal Trade Commission holds health claims to a standard of competent and reliable scientific evidence, which for health benefits generally means randomized, controlled human trials ⁷. Many peptides sold in clinics have mostly animal data behind them; our fact-check of popular claims shows how far apart the two can be.

8. What monitoring will you get?

Ask which blood tests are done before you start and how often afterwards, who reads them, and what result would make them stop or change the treatment. Monitoring that exists only on a brochure is not monitoring.

9. What are the risks, and will you sign consent that names them?

Informed consent should name the known risks of the specific product, the unknowns, and the alternatives, including approved drugs. For unapproved peptides the unknowns are large: FDA's stated concerns about BPC-157, for example, are possible immune reactions and difficulties with impurities and with characterising the active ingredient ⁶.

10. What will it cost in total?

Ask for the full price: consultation, lab tests, follow-up visits, the product and supplies, and whether the price changes with the dose. Our guide to what peptide therapy costs in 2026 sets out the published prices for approved drugs and what clinic quotes usually leave out.

11. Who do you call about side effects, and will they be reported?

Ask who answers if something goes wrong at night or at the weekend. Serious problems with any medical product can be reported to FDA through MedWatch, which takes reports from patients and consumers as well as clinicians ⁸; a careful clinic will tell you how it reports them.

12. Are you an athlete who is tested?

If you compete under anti-doping rules, ask before anything else. The World Anti-Doping Agency's 2026 and 2027 lists name BPC-157 among the non-approved substances prohibited at all times, and its rules cover many growth-hormone-related peptides as well ⁹. A clinic's view of a peptide's safety does not change its status in sport.

Red flags

Some answers should end the conversation. A product labelled for research use only, offered for injection. A claim that something is "FDA registered" presented as if it meant approved: registration applies to facilities such as outsourcing facilities ⁴, while compounded drugs themselves are not FDA-approved ³. Guaranteed results, or claims with no human studies behind them ⁷. No named prescriber, no pharmacy name, no certificate of analysis. And pressure to buy a long package before you have been assessed.

Frequently asked questions

How do I check a peptide clinic's prescriber?

Ask for the prescriber's name and licensing state, then check your state medical board's licence lookup. DocInfo, a free search run by the Federation of State Medical Boards, covers disciplinary history across every state.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy is state-licensed and overseen mainly by its state board of pharmacy. A 503B outsourcing facility registers with FDA, is inspected by FDA and must follow current good manufacturing practice. FDA publishes the list of registered facilities.

Are compounded peptides FDA-approved?

No. FDA states that compounded drugs are not FDA-approved. Registration of an outsourcing facility is not approval of the drugs it makes.

Can a clinic legally prescribe compounded BPC-157?

As of October 2, 2026, BPC-157 is in none of FDA's interim categories and not on the 503A list, so it has no recognised route to legal compounding.

Where can I report a side effect from a peptide?

Through FDA's MedWatch program, which accepts reports from patients and consumers as well as health professionals.

Related on Grey Peptides

• What peptide therapy really costs in 2026
• FDA's Category 1 and 2 explained
• What research use only really means
• Podcast peptide claims, fact-checked

Sources

1. ProPublica. Your Doctor Might Have a Disciplinary Record. Here's How to Find Out (projects.propublica.org), on state licence lookups and DocInfo; read October 2, 2026.
2. Federation of State Medical Boards. Statement describing DocInfo.org as its free physician search tool (via Newswise); read October 2, 2026.
3. US Food and Drug Administration. Compounding and the FDA: Questions and Answers (fda.gov), content current as of September 16, 2025; read October 2, 2026.
4. US Food and Drug Administration. Registered Outsourcing Facilities (fda.gov), content current as of September 30, 2026; read October 2, 2026.
5. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), updated May 14, 2026; read October 2, 2026.
6. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (fda.gov); BPC-157 added to 503A category 2 on September 29, 2023; read October 2, 2026.
7. Federal Trade Commission. Health Products Compliance Guidance (ftc.gov); read October 2, 2026.
8. US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program (fda.gov), content current as of September 25, 2026; read October 2, 2026.
9. World Anti-Doping Agency. The 2026 and 2027 Prohibited Lists, class S0 (non-approved substances), which names BPC-157; read October 2, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.